Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Papillary renal cell carcinoma, sporadic 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Basal Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

sonidegib 1folfirinox 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1HhAntag691 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms, Basal Cell × Erlotinib Hydrochloride × Clear all
NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡